DiagnosTear Grant Approval by the Israeli Office of the Chief Scientist

BioLight Life Sciences Investments announced today that on October 20, 2015, its subsidiary DiagnosTear Ltd., in which BioLight holds 70% of the issued and outstanding share capital, notified DiagnosTear that a third year approval for a grant from the Israeli Office of the Chief Scientist for a project with respect to the development of a diagnostic test intended for the diagnosis and monitoring of treatment of dry eye syndrome, was received and approved.

Link to complete article

Link to Newsroom

Comments are closed